アディポサイトブラウン:抗肥満療法における有望なアベニュー
Young-An Bae1, Hyae Gyeong Cheon2
1Department of Microbiology and Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon 21999, Republic of Korea.
International journal of molecular sciences
|February 13, 2026
まとめ
脂肪細胞の茶色化,白脂肪の熱性ベージュ細胞の形成は,エネルギー消費とインスリン感受性を高めます. このレビューでは,肥満と代謝疾患を標的とする分子調節物質とエージェントを調査します.
科学分野:
- 代謝生物学と内分泌学.
- 脂肪組織の生物学と可塑性.
背景:
- アディポサイト茶色化は,白色脂肪組織内の熱生成的に活発なベージュ色のアディポサイトの発達を伴う.
- ベージュ色のアディポサイトは,多局的脂質滴,高ミトコンドリア密度を示し,解離タンパク質1 (UCP1) を発現する.
- このプロセスは,PRDM16やPGC-1αのような分子調節体,表遺伝因子,非コーディングRNA,ホルモン信号の影響を受けます.
研究 の 目的:
- 脂肪細胞の茶色化を調節する分子機構をレビューする.
- 脂肪細胞の茶色化を誘発する既存のおよび新しい薬剤を試験する.
- 代謝疾患の介入におけるアディポサイト茶色化の可能性について議論する.
主な方法:
- アディポサイト茶色化の分子調節剤に関する文献レビュー.
- ブラウン化を促す環境的シグナル (風邪,運動,カロリー制限) の分析.
- 茶色化剤としての天然製品,再定位薬,新しい化学物質の調査.
主要な成果:
- 脂肪細胞の茶色化は,エネルギー消費を高め,インスリン感受性を改善し,脂質の蓄積を減少させます.
- 環境要因と分子ネットワークは,脂肪組織の可塑性を決定的に調節する.
- いくつかの茶色化剤は有望であることが示されていますが,翻訳上の課題は残っています.
結論:
- 脂肪細胞の茶色化は,代謝健康を改善するための重要なメカニズムです.
- 脂肪細胞の茶色化をターゲットにすることは,肥満と2型糖尿病の潜在的な治療戦略を提供します.
- ヒトへの応用における翻訳上の障害を克服するために,さらなる研究が必要である.
関連する概念動画
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Group Therapy
469
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
469
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
296
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
296
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197


